case 2: nccn guidelines for treating polycythemia vera
Published 4 years ago • 100 plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
4:58
case 1: genomic testing & nccn guidelines for metastatic crc
-
2:36
the evolving treatment landscape of polycythemia vera
-
6:07
available treatment options for patients with pv
-
2:57
nccn guidelines for castleman’s disease
-
3:15
treatment options for high-risk polycythemia vera
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
1:59
currently accepted regimens: nccn guidelines
-
5:21
case 2: choosing the right treatment option
-
4:15
case 2: treatment considerations in stage iv nsclc
-
4:37
the use of ruxolitinib in mpn
-
1:00:46
understanding the nccn clinical practice guidelines for histiocytic neoplasms
-
3:53
heterogeneity of polycythemia vera
-
8:24
nccn guidelines (v.1.2020)
-
4:01
the role of jak2 inhibition in patients with pv
-
5:36
considerations for starting cytoreductive therapy in pv
-
1:44
evolving nccn guidelines for mpns
-
4:28
dual checkpoint inhibition in nsclc
-
50:19
conversation with an mpn specialist: summer updates